Peptides, Pain & Inflammation
BPC-157 / TB-500 · 15 mg injection
Investigational · Not FDA approved
BPC-157/TB-500 (Wolverine)
Rx
Wolverine is a marketed blend of BPC-157 and TB-500. Neither is FDA approved. No controlled human trial has tested the combination, and the only direct controlled comparison is a small rat study.
Starting at
$125
/ mo
What the evidence actually shows
The Wolverine blend combines BPC-157 with TB-500 on the theory that their tissue-repair effects are complementary. Neither is FDA approved, and no controlled human trial has tested the combination. One 2026 rat study found no additional benefit from combining them over either peptide alone.
HUMAN EVIDENCE
No controlled human trial has tested the BPC-157/TB-500 blend for pain, healing, function or return to activity.
CONTROLLED EFFICACY
The only direct controlled comparison was in rats; four tendon samples per group were assessed for each analytical endpoint.
LONG-TERM SAFETY
No human study has evaluated the blend's safety, dose, interactions or long-term risks.
Regulatory status
Neither BPC-157 nor TB-500 is FDA approved. FDA's current compounding safety-risk page says it identified no human exposure data for TB-500 and describes characterization and immunogenicity concerns for both substances. Both were included in FDA's July 2026 advisory-committee review; advisory review is not approval. BPC-157 and TB-500 are prohibited under WADA rules.
HUMAN AND PRECLINICAL EVIDENCE
What the research shows
The evidence is not all equal. Human observations and animal findings are separated below so they cannot be mistaken for the same level of support.
Direct evidence · Rat Achilles study
A 2026 study randomized 32 rats into four groups of eight after Achilles tendon repair. Only four tendons per group were used for each analytical endpoint. The combination improved one histology comparison versus control but did not add benefit over either peptide alone.
Human evidence · Exact blend not studied
No controlled human trial has tested BPC-157 with TB-500. Small uncontrolled BPC-157 reports cannot establish benefit for the blend, and FDA says it has not identified human exposure data for the TB-500 fragment.
Product identity · Similar names, different molecules
TB-500 is related to, but is not the same molecule as, full-length thymosin beta-4. The distinction matters because human reports involving thymosin beta-4 do not establish the safety or effectiveness of TB-500 or this blend.
WHAT THIS MEANS
What this means: the combination has a plausible preclinical rationale, but it has no controlled human outcome evidence. The only direct controlled comparison was small, animal-based and did not show that the blend outperformed either peptide alone.
What is BPC-157/TB-500 (Wolverine)?
Wolverine is a marketed blend of BPC-157 and TB-500. Neither is FDA approved. No controlled human trial has tested the combination, and the only direct controlled comparison is a small rat study.
Wolverine is a marketing name for a blend of BPC-157 and TB-500. BPC-157 is a synthetic 15-amino-acid peptide studied mainly in animals. TB-500 is a short synthetic fragment related to thymosin beta-4, the full 43-amino-acid protein. Evidence involving full-length thymosin beta-4 cannot automatically be applied to TB-500.
PRECLINICAL EVIDENCE
BPC-157 is studied for angiogenesis and nitric-oxide-related signaling, while TB-500 is studied for actin regulation and cell migration. Combining those mechanisms is a hypothesis. Additive mechanisms do not guarantee better outcomes, and the only direct controlled comparison did not show an advantage over either peptide alone.
A plausible mechanism is not evidence of clinical benefit.
Safety limits and suitability
The available human evidence is too limited to establish a standard treatment pathway. These points are presented for medical review and informed discussion.
What is not known
The exact ingredient forms and ratio in the 15 mg blend remain to be confirmed. No controlled human trial has established benefit, dose, safety, interactions or long-term outcomes for the combination. It is also unknown whether evidence involving full-length thymosin beta-4 transfers to the shorter TB-500 fragment.
Who should not use it
Formal contraindications have not been established in human trials. Draft clinical cautions include active or previous cancer, pregnancy or breastfeeding, trying to conceive, undiagnosed injury, planned or recent orthopedic surgery without surgeon involvement, and participation in drug-tested sport. Final wording requires medical approval.
When telehealth is not the right setting
In-person or urgent assessment may be more appropriate for an acute injury that has not been examined or imaged, suspected tendon rupture or fracture, worsening or night pain, pain with fever, suspected infection, suspected malignancy, or planned or recent orthopedic surgery. The final list must match Peptela's actual intake and escalation protocol.
Monitoring and expectations
No validated monitoring schedule exists for this unapproved combination. The final Peptela plan must define baseline diagnosis and examination requirements, follow-up timing, symptom and injection-site checks, stop criteria, and urgent escalation rules. Those details remain pending medical approval.
MEDICAL REVIEW
Dr. Reza Omid
MD
Medical content draft supplied · Final review and sign-off pending
Review date
Selected medical and regulatory references
Primary and regulatory sources used for the current draft. The final reference list remains under medical review.
Frequently asked questions
Start with a clinical evaluation
Diagnosis and suitability come before a product decision. Completing the intake does not guarantee that a clinician will prescribe treatment.